Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
about
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEAElevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot studyDiagnostic and prognostic tumor markers in the gastrointestinal tract.AB0 blood group and prognosis in patients with pancreatic cancer.CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution.Oncofetal markers CA 19-9, CA 125 and SP1 in healthy children and in children with malignancyCAM 17.1--a new diagnostic marker in pancreatic cancer.Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancerStrategies for discovering novel pancreatic cancer biomarkers.Clinical significance of CA19-9 in diagnosis of digestive tract tumorsLaminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissuesCA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis.Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEAThe diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9.A diaphragmatic retroperitoneal cyst.Tumour marker CA 125 in patients with digestive tract malignancies.Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.Identification of the peanut-agglutinin binding pancreatic cancer serum marker in pancreatic tissue extractsTissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9.CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
P2860
Q24678824-DD62ECB1-155D-439A-9042-508979604992Q33780907-60DD8F74-2D82-47FD-955D-1AD26CD2CD51Q34277292-16121309-DC0A-47AD-853E-DA83FAE7A4C2Q34354138-D92A77B8-31A7-45ED-A018-A0AA65BFC798Q34646563-6DF0E16E-0CAA-4621-8FE1-FCC015E5652DQ35046670-C8D0C35F-B27F-42C1-91B0-89D15AEF0F55Q35982122-047CB2B0-382E-4E31-A613-4B9EC55E735AQ36136408-F153B166-315E-4D13-A158-E3F2A253D2CFQ36294910-46ECC173-4E7D-4CD0-B156-23E1317923F8Q36466555-15F271C3-D307-4E9C-8B59-210B6E57704FQ36579311-EEA8AD62-60DA-433E-AF16-9E5E73C4994CQ36724560-FD155EAB-6752-4908-AF11-A635AFE0FB71Q37214680-91495A5C-0EDF-4CCB-9D3A-9CC06969E756Q37400577-909385AE-955B-433A-B285-1D8485D81FF7Q37617965-9CBE5108-5A89-4E3D-B2A3-9C31E5A8C523Q40877957-94F8CF8C-1F82-4D63-8FAB-D8FC827FA37DQ41139267-AAE4122E-CC1A-4D78-86D6-A0629AA452C8Q41143940-816E2ED1-1548-4C00-9AD9-1A585C7B3654Q41145865-4A0206E5-C82F-40F5-BB8B-33E980C18E00Q41151406-E2D1B5B5-AD40-488B-AA66-CFD44C711E53Q41677422-FE07E1CB-B9AD-489E-A857-2173CFAF3358Q41686326-A7F397E6-E3A0-422B-8F69-ACCFBD0DA2ACQ41761881-971EF68D-6029-459F-89C0-02FF65FA3E5BQ41819905-8A6849BD-A2BB-4E31-B9CC-19BAE9524F68Q41901332-A5CF2F47-3DEB-4FD7-AD6E-77770CFD0B05Q42023730-221994AC-E542-45CC-AF92-B7F7650914E9Q42384437-86FD8B08-7A46-416C-8D5C-7C1C5D23ABCDQ43051293-927CEF16-EA47-430C-9194-CF90F5E9A962Q44168017-FB6FBBC3-FF41-4B01-9055-777F8402F62EQ46194311-05B9526D-A748-4B02-949E-F82E8FD1C33A
P2860
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
@en
type
label
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
@en
prefLabel
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
@en
P2093
P2860
P356
P1476
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1986.35
P407
P577
1986-02-01T00:00:00Z